Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV001073456 | SCV001238998 | pathogenic | Retinal dystrophy | 2019-02-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000086109 | SCV001395487 | pathogenic | not provided | 2024-11-18 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with histidine, which is basic and polar, at codon 85 of the BEST1 protein (p.Tyr85His). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with autosomal dominant Best vitelliform macular dystrophy (PMID: 20375334, 21473666). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 2728). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt BEST1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects BEST1 function (PMID: 11904445, 17110374, 21330666, 23880862). For these reasons, this variant has been classified as Pathogenic. |
Institute of Human Genetics, |
RCV001073456 | SCV005070669 | pathogenic | Retinal dystrophy | 2017-01-01 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000002847 | SCV000023005 | pathogenic | Vitelliform macular dystrophy 2 | 1998-07-01 | no assertion criteria provided | literature only | |
Retina International | RCV000086109 | SCV000118253 | not provided | not provided | no assertion provided | not provided | ||
Department of Clinical Genetics, |
RCV000002847 | SCV000926510 | likely pathogenic | Vitelliform macular dystrophy 2 | 2018-04-01 | no assertion criteria provided | research |